All In Biotech

Drug Trial Radar · NCT03930953

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).

Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

438

Planned (sponsor's estimate)

Start

May 20, 2019

Primary completion

Apr 7, 2027

Study completion Feb 9, 2028

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • CC-99282Drug

    Specified dose on specified days

  • RituximabDrug

    Specified dose on specified days

  • ObinutuzumabDrug

    Specified dose on specified days

  • TafasitamabDrug

    Specified dose on specified days

  • ValemetostatDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
  2. Number of participants with laboratory abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
  3. Number of participants with vital sign abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
  4. Number of participants with electrocardiogram (ECG) abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
  5. Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
  6. Number of participants with left ventricular ejection fraction (LVEF) assessment abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
  7. Number of participants with physical examination abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
  8. Dose Limiting Toxicity (DLT)Time frame: Up to 28 days in Cycle 1
  9. Maximum tolerated dose (MTD)Time frame: Up to 28 days in cycle 1

Locations

66 sites in 15 countries. Site status is shown where the registry gives one.

  • Local Institution - 109

    Scottsdale, Arizona

  • Local Institution - 111

    Jacksonville, Florida

  • Local Institution - 102

    Tampa, Florida

  • Local Institution - 108

    Overland Park, Kansas

  • Local Institution - 107

    Rochester, Minnesota

  • Local Institution - 104

    St Louis, Missouri

  • Local Institution - 103

    Hackensack, New Jersey

  • Local Institution - 101

    Houston, Texas

  • Local Institution - 253

    Buenos Aires, Argentina

  • Local Institution - 255

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Local Institution - 254

    Pilar, Buenos Aires, Argentina

  • Local Institution - 701

    Salzburg, Austria

  • Local Institution - 704

    Sankt Pölten, Austria

  • Local Institution - 703

    Vienna, Austria

  • Local Institution - 902

    Leuven, Belgium

  • Local Institution - 451

    São Paulo, Brazil

  • Local Institution - 452

    São Paulo, Brazil

  • Local Institution - 453

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution - 450

    São Paulo, São Paulo, Brazil

  • Local Institution - 201

    Toronto, Ontario, Canada

  • Local Institution - 354

    Santiago, Metropolitana de Santiago, Chile

  • Local Institution - 350

    Santiago, RM, Chile

  • Local Institution - 355

    Recoleta, Santiago Metropolitan, Chile

  • Local Institution - 353

    Santiago, Santiago Metropolitan, Chile

  • Local Institution - 352

    Santiago, Santiago Metropolitan, Chile

  • Local Institution - 659

    Guangzhou, China

  • Local Institution - 653

    Beijing, Beijing Municipality, China

  • Local Institution - 657

    Guangzhou, Guangdong, China

  • Local Institution - 655

    Zhengzhou, Henan, China

  • Local Institution - 660

    Wuhan, Hubei, China

  • Local Institution - 662

    Shenyang, Liaoning, China

  • Local Institution - 663

    Shenyang, Liaoning, China

  • Local Institution - 650

    Shanghai, Shanghai Municipality, China

  • Local Institution - 651

    Tianjin, Tianjin Municipality, China

  • Local Institution - 602

    Aarhus, Denmark

  • Local Institution - 601

    Copenhagen, Denmark

  • Local Institution - 603

    Vejle, Denmark

  • Local Institution - 407

    Bordeaux, France

  • Local Institution - 403

    Créteil, France

  • Local Institution - 406

    Lille, France

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.